Paper Details

  1. Home
  2. Paper Details

Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10.

Author: DrewYvette, HarisNoor Md, KristeleitRebecca S, OakninAna, Ray-CoquardIsabelle, SwisherElizabeth M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review examines the safety and tolerability of rucaparib, a poly(ADP-ribose) polymerase inhibitor, in the treatment setting for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy. It provides practical recommendations for managing common side effects, such as anemia, blood creatinine elevations, and gastrointestinal issues.
Paper Details　
Original Abstract of the Article :
Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. As more on...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964123/

データ提供：米国国立医学図書館（NLM）

Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Navigating the Shifting Sands of Treatment

Ovarian cancer, like a treacherous desert storm, is a formidable foe. Recent advancements in cancer therapy have brought new hope with the emergence of PARP inhibitors, such as rucaparib. This research explores the real-world delivery of rucaparib to patients with recurrent ovarian cancer, emphasizing the need for a nuanced understanding of its safety and tolerability. Drawing upon data from the ARIEL2 clinical trial and their own experience, the authors provide recommendations for managing potential side effects, including anemia, blood creatinine elevations, liver enzyme elevations, thrombocytopenia, gastrointestinal events, and fatigue. They emphasize that many of these side effects, like temporary desert mirages, are manageable with appropriate interventions such as treatment interruption, dose reduction, and supportive therapies. By navigating these potential challenges, patients can maximize the benefits of rucaparib treatment.

Navigating the Shifting Sands of Ovarian Cancer Treatment

This research provides a crucial roadmap for navigating the complexities of rucaparib treatment for ovarian cancer. By understanding potential side effects and implementing appropriate strategies, healthcare professionals can help patients traverse the challenging terrain of this disease and maximize their chances of achieving positive outcomes.

A Journey Through the Desert of Ovarian Cancer

This research sheds light on the importance of thoughtful and strategic approaches to managing the side effects of rucaparib treatment for ovarian cancer. By working collaboratively with healthcare professionals, patients can confidently navigate the challenging terrain of this disease and maximize their chances of achieving positive outcomes.

Dr. Camel's Conclusion

This research provides a valuable resource for healthcare professionals and patients navigating the complexities of rucaparib treatment for ovarian cancer. It emphasizes the importance of a collaborative approach to managing potential side effects, ensuring that patients can traverse the challenging terrain of this disease and maximize their chances of achieving positive outcomes.
Date :
  1. Date Completed 2020-12-08
  2. Date Revised 2023-09-14
Further Info :

Pubmed ID

31575788

DOI: Digital Object Identifier

PMC6964123

Related Literature

Article Analysis
・Side Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.